Regulatory B cells in transplantation: roadmaps to clinic.
Joseph BeckettJoanna HesterFadi IssaSushma ShankarPublished in: Transplant international : official journal of the European Society for Organ Transplantation (2020)
Over the last two decades, an additional and important role for B cells has been established in immune regulation. Preclinical studies demonstrate that regulatory B cells (Breg) can prolong allograft survival in animal models and induce regulatory T cells. Operationally tolerant human kidney transplant recipients demonstrate B-cell-associated gene signatures of immune tolerance, and novel therapeutic agents can induce Bregs in phase I clinical trials in transplantation. Our rapidly expanding appreciation of this novel B-cell subtype has made the road to clinical application a reality. Here, we outline several translational pathways by which Bregs could soon be introduced to the transplant clinic.
Keyphrases
- regulatory t cells
- clinical trial
- cell therapy
- primary care
- dendritic cells
- transcription factor
- genome wide
- endothelial cells
- copy number
- induced pluripotent stem cells
- dna methylation
- pluripotent stem cells
- kidney transplantation
- immune response
- case control
- randomized controlled trial
- free survival
- bone marrow
- genome wide identification
- open label
- genome wide analysis